Treatment-emergent endocrine symptoms and the risk of breast cancer recurrence: a retrospective analysis of the ATAC trial

The Lancet Oncology

Volumn 9, Issue 12, 2008, Pages 1143-1148

  Cuzick, Jack ^a   Sestak, Ivana ^a   Cella, David ^b   Fallowfield, Lesley ^c  

^a QUEEN MARY UNIVERSITY OF LONDON   (United Kingdom)

^b EVANSTON HOSPITAL   (United States)

^c BRIGHTON AND SUSSEX MEDICAL SCHOOL   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANASTROZOLE; TAMOXIFEN;

AGE; ARTHRALGIA; ARTHRITIS; ARTHROPATHY; ARTICLE; AWARENESS; BODY MASS; BREAST CANCER; CANCER ADJUVANT THERAPY; CANCER GRADING; CANCER RECURRENCE; CLINICAL TRIAL; COLD SWEAT; COMBINATION CHEMOTHERAPY; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG EFFICACY; DRUG TOLERABILITY; DRUG WITHDRAWAL; ENDOCRINE DISEASE; FEMALE; FOLLOW UP; HAZARD RATIO; HORMONE SUBSTITUTION; HOT FLUSH; HUMAN; LONG TERM CARE; MAJOR CLINICAL STUDY; MORNING DOSAGE; NIGHT SWEAT; OSTEOARTHRITIS; POSTMENOPAUSE; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL; RECURRENCE RISK; RETROSPECTIVE STUDY; SYMPTOM; TUMOR VOLUME; VASOMOTOR DISORDER;

ADULT; AGED; ANTINEOPLASTIC AGENTS, HORMONAL; ARTHRALGIA; BREAST NEOPLASMS; FEMALE; HOT FLASHES; HUMANS; JOINTS; MIDDLE AGED; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS, HORMONE-DEPENDENT; NITRILES; ODDS RATIO; POSTMENOPAUSE; PREDICTIVE VALUE OF TESTS; RANDOMIZED CONTROLLED TRIALS AS TOPIC; RECEPTORS, ESTROGEN; RECEPTORS, PROGESTERONE; RETROSPECTIVE STUDIES; TAMOXIFEN; TREATMENT OUTCOME; TRIAZOLES; TUMOR MARKERS, BIOLOGICAL; VASOMOTOR SYSTEM;

EID: 56449112123     PISSN: 14702045     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1470-2045(08)70259-6     Document Type: Article

References (28)

1. Baron F., Maris M.B., Sandmaier B.M., et al. Graft-versus-tumor effects after allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. J Clin Oncol 23 (2005) 1993-2003
2. Perez-Simon J.A., Martino R., Alegre A., et al. Chronic but not acute graft-versus-host disease improves outcome in multiple myeloma patients after non-myeloablative allogeneic transplantation. Br J Haematol 121 (2003) 104-108
3. Mohty M., Boiron J.M., Damaj G., et al. Graft-versus-myeloma effect following antithymocyte globulin-based reduced intensity conditioning allogeneic stem cell transplantation. Bone Marrow Transplant 34 (2004) 77-84
4. Petersen S.L. Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning. Dan Med Bull 54 (2007) 112-139
5. Perez-Soler R., and Saltz L. Cutaneous adverse effects with HER1/EGFR-targeted agents: is there a silver lining?. J Clin Oncol 23 (2005) 5235-5246
6. Cohen E.E. Role of epidermal growth factor receptor pathway-targeted therapy in patients with recurrent and/or metastatic squamous cell carcinoma of the head and neck. J Clin Oncol 24 (2006) 2659-2665
7. Buzdar A.U., Jonat W., Howell A., et al. Anastrozole versus megestrol acetate in the treatment of postmenopausal women with advanced breast carcinoma: results of a survival update based on a combined analysis of data from two mature phase III trials. Arimidex Study Group. Cancer 83 (1998) 1142-1152
8. Rutqvist L.E., Johansson H., Signomklao T., Johansson U., Fornander T., and Wilking N. Adjuvant tamoxifen therapy for early stage breast cancer and second primary malignancies. Stockholm Breast Cancer Study Group. J Natl Cancer Inst 87 (1995) 645-651
9. Baum M., Budzar A.U., Cuzick J., et al. Anastrozole alone or in combination with tamoxifen versus tamoxifen alone for adjuvant treatment of postmenopausal women with early breast cancer: first results of the ATAC randomised trial. Lancet 359 (2002) 2131-2139
10. Coates A.S., Keshaviah A., Thurlimann B., et al. Five years of letrozole compared with tamoxifen as initial adjuvant therapy for postmenopausal women with endocrine-responsive early breast cancer: update of study BIG 1-98. J Clin Oncol 25 (2007) 486-492
11. Forbes J.F., Cuzick J., Buzdar A., Howell A., Tobias J.S., and Baum M. Effect of anastrozole and tamoxifen as adjuvant treatment for early-stage breast cancer: 100-month analysis of the ATAC trial. Lancet Oncol 9 (2008) 45-53
12. Goss P.E., Ingle J.N., Martino S., et al. A randomized trial of letrozole in postmenopausal women after five years of tamoxifen therapy for early-stage breast cancer. N Engl J Med 349 (2003) 1793-1802
13. Goetz M.P., Knox S.K., Suman V.J., et al. The impact of cytochrome P450 2D6 metabolism in women receiving adjuvant tamoxifen. Breast Cancer Res Treat 101 (2007) 113-121
14. Goetz M.P., Rae J.M., Suman V.J., et al. Pharmacogenetics of tamoxifen biotransformation is associated with clinical outcomes of efficacy and hot flashes. J Clin Oncol 23 (2005) 9312-9318
15. Sachse C., Brockmoller J., Bauer S., and Roots I. Cytochrome P450 2D6 variants in a Caucasian population: allele frequencies and phenotypic consequences. Am J Hum Genet 60 (1997) 284-295
16. Mortimer J.E., Flatt S.W., Parker B.A., et al. Tamoxifen, hot flashes and recurrence in breast cancer. Breast Cancer Res Treat 108 (2008) 421-426
17. Coombes R.C., Hall E., Gibson L.J., et al. A randomized trial of exemestane after two to three years of tamoxifen therapy in postmenopausal women with primary breast cancer. N Engl J Med 350 (2004) 1081-1092
18. Donnellan P.P., Douglas S.L., Cameron D.A., and Leonard R.C. Aromatase inhibitors and arthralgia. J Clin Oncol 19 (2001) 2767
19. Howell A., Cuzick J., Baum M., et al. Results of the ATAC (Arimidex, Tamoxifen, Alone or in Combination) trial after completion of 5 years' adjuvant treatment for breast cancer. Lancet 365 (2005) 60-62
20. Fallowfield L.J., Leaity S.K., Howell A., Benson S., and Cella D. Assessment of quality of life in women undergoing hormonal therapy for breast cancer: validation of an endocrine symptom subscale for the FACT-B. Breast Cancer Res Treat 55 (1999) 189-199
21. Fallowfield L., Cella D., Cuzick J., Francis S., Locker G., and Howell A. Quality of life of postmenopausal women in the Arimidex, Tamoxifen, Alone or in Combination (ATAC) Adjuvant Breast Cancer Trial. J Clin Oncol 22 (2004) 4261-4271
22. Cox D.R. Regression models and life tables. J R Stat Soc 34 (1972) 187-220
23. Kaplan E.L., and Meier P. Nonparametric estimation from incomplete observations. J Am Stat Assoc 53 (1958) 457-481
24. Bonanni B., Macis D., Maisonneuve P., et al. Polymorphism in the CYP2D6 tamoxifen-metabolizing gene influences clinical effect but not hot flashes: data from the Italian Tamoxifen Trial. J Clin Oncol 24 (2006) 3708-3709
25. Siegelmann-Danieli N., and Buetow K.H. Constitutional genetic variation at the human aromatase gene (Cyp19) and breast cancer risk. Br J Cancer 79 (1999) 456-463
26. Chlebowski R.T., and Geller M.L. Adherence to endocrine therapy for breast cancer. Oncology 71 (2006) 1-9
27. Guth U., Huang D.J., Schotzau A., et al. Target and reality of adjuvant endocrine therapy in postmenopausal patients with invasive breast cancer. Br J Cancer 99 (2008) 428-433
28. Fallowfield L. There's many a slip twixt cup and lip: adherence issues in cancer therapy. Nat Clin Pract Oncol 5 (2008) 118-119